Objective: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME).
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vessel permeability in vivo possibly by increasing the phosphorylation of tight junction proteins. 7 Therefore, therapy that inhibits VEGF may represent a useful therapeutic modality that targets the underlying pathogenesis of DME. Pegaptanib (Macugen, Eyetech Pharmaceuticals, Palm Beach Gardens, FL) was the first anti-VEGF drug reported to have a favorable effect on macular edema, 8 although more recently, the anti-VEGF drugs ranibizumab (Lucentis, Genentech, South San Francisco, CA) and bevacizumab (Avastin, Genentech), among others, also have been evaluated for DME. Prior studies, which were small with short-term follow-up, have reported promising results. 9 Intravitreal triamcinolone also was evaluated previously as treatment for DME in a randomized trial conducted by the DRCR.net. 5 Although the data suggest that triamcinolone treatment was superior to the expected untreated course in the ETDRS, it was not superior to focal/grid photocoagulation. 5 The combination of intravitreal treatment (either triamcinolone or an anti-VEGF drug) with focal/grid photocoagulation, theoretically, could be more effective than either treatment alone. The intravitreal treatment might rapidly reduce macular edema and lead to more rapid visual acuity improvement, whereas slower benefit accrues over time as a result of laser treatment. In addition, combined treatment could enhance the effect of focal/grid photocoagulation because the retina would be less edematous if laser treatment was administered some time after the intravitreal treatment reduced macular edema. Also, laser treatment theoretically could reduce the number of repeat intravitreal injections required to optimize the outcome of DME treatment. In a study of 86 eyes randomized to 4 mg intravitreal triamcinolone alone or followed by macular laser photocoagulation, Kang et al 10 reported that after 6 months visual acuity was better and more eyes had resolution of central edema with the combined treatment when compared with intravitreal triamcinolone without macular laser. Other studies have shown greater mean visual acuity improvements at 6 months using ranibizumab ϩ laser, or ranibizumab alone, when compared with laser alone. 9 To determine whether anti-VEGF therapy alone or in combination with focal/grid laser, or intravitreal triamcinolone combined with focal/grid laser, might result in improved outcomes compared with the standard treatment for DME of laser alone, the DRCR.net designed a clinical trial to evaluate 3 treatment modalities for DME in comparison with focal/grid photocoagulation: ranibizumab combined with prompt (within 1 week) focal/grid photocoagulation, intravitreal triamcinolone combined with prompt (within 1 week) focal/grid photocoagulation, and intravitreal ranibizumab with focal/grid photocoagulation deferred for at least 24 weeks. The study design also provided an opportunity to determine which regimen resulted in fewer treatments if safety and efficacy were comparable.
Materials and Methods
This phase 3 randomized, multicenter clinical trial was conducted by the DRCR.net at 52 clinical sites in the United States. The study adhered to the tenets of the Declaration of Helsinki. The protocol and informed consent forms were compliant with the Health Insurance Portability and Accountability Act and approved by multiple institutional review boards. Each study participant gave written informed consent before participation in the study. Study oversight was provided by an independent data and safety monitoring committee. The study was conducted under an Investigational New Drug Application from the Food and Drug Administration. The study is listed on www.clinicaltrials.gov under identifier NCT00445003 (website registration date 03-06-2007) , and the protocol is available on the DRCR.net website (www.drcr. net, date accessed January 1, 2010) . Key aspects of the protocol pertinent to this article are summarized next.
Study Population
Eligible patients were at least 18 years old with type 1 or 2 diabetes. The major eligibility criteria for a study eye included the following: (1) best-corrected Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS Visual Acuity Test 11 ) visual acuity letter score 78 to 24 (20/32-20/320), (2) definite retinal thickening due to DME on clinical examination involving the center of the macula assessed to be the main cause of visual loss, and (3) retinal thickness measured on time domain optical coherence tomography (OCT) Ն250 m in the central subfield. Principal exclusion criteria included the following: (1) treatment for DME within the prior 4 months, (2) panretinal photocoagulation within the prior 4 months or anticipated need for panretinal photocoagulation within the next 6 months, (3) major ocular surgery within the prior 4 months, (4) history of open-angle glaucoma or steroid-induced intraocular pressure (IOP) elevation that required IOP-lowering treatment, and (5) IOP Ն25 mmHg. Patients were excluded if their systolic blood pressure was Ͼ180 mmHg or diastolic blood pressure was Ͼ110 mmHg, or if a myocardial infarction, other cardiac event requiring hospitalization, cerebrovascular accident, transient ischemic attack, or treatment for acute congestive heart failure occurred within 4 months before randomization. A patient could have 2 study eyes in the trial only if both were eligible at the time of study entry.
Synopsis of Study Design
After eligibility was determined and informed consent was obtained, study participants with 1 study eye were assigned randomly on the DRCR.net study website (using a permuted blocks design stratified by study eye visual acuity) with equal probability to 1 of 4 treatment groups: (1) sham injection plus prompt (within 3-10 days after injection) focal/grid photocoagulation (sham ϩ prompt laser group), (2) 0.5 mg intravitreal ranibizumab plus prompt (within 3-10 days after injection) focal/grid photocoagulation (ranibizumab ϩ prompt laser group), (3) 0.5 mg intravitreal ranibizumab with deferred (Ն24 weeks) focal/grid photocoagulation (ranibizumab ϩ deferred laser group), and (4) 4 mg intravitreal triamcinolone plus prompt (within 3-10 days after injection) focal/ grid photocoagulation (triamcinolone ϩ prompt laser group). For study participants with 2 study eyes, the right eye was assigned randomly with equal probability to 1 of the 4 groups as indicated above. If the right eye was assigned to a treatment group other than the sham ϩ prompt laser group, then the left eye was assigned to the sham ϩ prompt laser group. If the right eye was assigned to the sham ϩ prompt laser group, then the left eye was assigned randomly to 1 of the other 3 groups. Thus, there were more eyes in the sham ϩ prompt laser group than in the other 3 groups.
Follow-up was planned for 3 years, with the primary outcome at 1 year. During the first year, follow-up visits occurred every 4 weeks (Ϯ1 week). Study participants in the 3 groups receiving laser were masked to treatment assignment through the primary Ophthalmology Volume xx, Number x, Month 2010 2 
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outcome visit, whereas the ranibizumab ϩ deferred laser group was not masked. After the first year, visits occurred every 4 to 16 weeks depending on the treatment group, disease course, and treatment administered. After a study participant completed the primary outcome visual acuity examination at 1 year, the study participant was made aware of his or her treatment group assignment and sham injections were discontinued. Visual acuity examiners and OCT technicians were masked to treatment group assignment before and at the 1-year primary outcome visit.
Examination Procedures
At baseline and each follow-up visit, best-corrected visual acuity letter score was measured at 3 m by a certified examiner using an E-ETDRS Visual Acuity Test. 11 The OCT images were obtained at baseline and each follow-up visit by a certified operator using the Zeiss Stratus OCT (OCT3) machine (Carl Zeiss Meditec, Inc., Dublin, CA) . Scans were 6 mm in length and included the 6-radial line fast macular scan pattern for quantitative measures and the cross-hair pattern (6 -12 o'clock and 9 -3 o'clock) for qualitative assessment of retinal morphology. All baseline OCT scans, annual follow-up scans with a standard deviation of the center point Ն10.0%, and scans from any visits in which the investigator suspected erroneous measurements because of the algorithm placement of the lines created by the OCT software that delineate the inner and outer aspects of the retina were sent to the Fundus Photograph Reading Center (University of Wisconsin, Madison) for grading. If the automated thickness measurements were judged by the Reading Center to be inaccurate on any submitted image, center point thickness was measured manually, and this value was used to impute a value for the central subfield based on a correlation of the 2 measures of 0.98 as published previously 12 (20% of 854 baseline scans were imputed and 1 scan was unable to be manually graded at baseline, and 2% of 10 849 follow-up scans were imputed and 22 [Ͻ1%] were unable to be manually graded during follow-up through 1 year). Manual grading of the baseline scans resulted in an imputed baseline central subfield value Ͻ250 m for 60 eyes (7%), which does not necessarily mean that the true thickness measurement is Ͻ250 if measureable. Of note, 22 (37%) of the 60 scans with an imputed central subfield thickness Ͻ250 m were from 1 clinical site and represented 85% of the 26 baseline scans from that site. All intent-to-treat results presented were similar when evaluated with exclusion of eyes from that clinical site (data not shown) and when evaluated with exclusion of eyes from any clinical site with a baseline central subfield thickness Ͻ250 m. Baseline OCT images also were assessed by the Reading Center for cystoid abnormalities and subretinal fluid.
Additional testing at baseline and each follow-up visit included slit-lamp examination, measurement of IOP, and fundus examination after pupil dilation. Standard ETDRS 7-field color stereoscopic fundus photographs were obtained at baseline and 12 months by a certified photographer and graded at the reading center for level of diabetic retinopathy.
13 Hemoglobin A1c was measured at baseline. Any untoward medical occurrence, regardless of whether the event was considered treatment related, was considered as an adverse event and recorded. Treatment of adverse events and proliferative diabetic retinopathy was at the discretion of the investigator.
Treatment Protocol
Overview. The treatment protocol (summarized in Appendix 1, available at http://aaojournal.org) included a baseline treatment followed by intravitreal study drug or sham injection retreatments every 4 weeks through the 12-week study visit. From the 16-week study visit and thereafter, a retreatment algorithm for study drug injections and sham injections (Appendices 2 and 3, available at http://aaojournal.org) was designed to require retreatments unless a study visit was deemed a 'success' (defined below and in Table  1 , available at http://aaojournal.org) at which point retreatment was at investigator discretion. From the 24-week study visit and thereafter retreatment was at investigator discretion if the study visit was deemed 'no improvement' (defined in Table 1 , available at http://aaojournal.org). If retreatment with a study drug or sham injection was not given, 'alternative treatment' (defined in Table 1 , available at http://aaojournal.org) was permitted only if a study eye met criteria for 'failure' or 'futility' (defined in Table 1 , available at http://aaojournal.org). When retreatment with a study drug or sham injection was indicated, eyes assigned to one of the ranibizumab groups could receive ranibizumab as often as every 4 weeks; eyes assigned to intravitreal triamcinolone could receive triamcinolone as often as every 16 weeks with sham injections as often as every 4 weeks in between triamcinolone injections; eyes assigned to sham ϩ prompt laser could receive sham injections as often as every 4 weeks. A retreatment algorithm for focal/grid laser (Appendix 4, available at http://aaojournal.org) was designed to require retreatment if there was 'edema involving the center of the macula' or 'edema threatening the center of the macula' (defined in Table 1 , available at http://aaojournal.org) and if 'complete laser' had not been given (defined in Table 1 , available at http:// aaojournal.org), provided that it had been at least 13 weeks since the last focal/grid laser application.
Retreatment Algorithm System. Compliance with the details of the treatment protocol, which depended mainly on visual acuity and OCT measurements over time, was facilitated by a web-based, real-time data-entry system. At each follow-up visit, the system provided real-time feedback to the treating physician regarding whether treatment was required or at investigator discretion. If treatment was to be given, the system also provided feedback as to whether the treatment should be an intravitreal study drug or sham injection, whether focal/grid photocoagulation should be applied, and what the next follow-up interval should be.
Statistical Methods
Data are reported that were collected by the clinical sites from March 2007 to February 8, 2010 . This includes at least 1-year follow-up for the entire study population and up to 2-year follow-up for participants enrolled early in the trial. Mean change in visual acuity from baseline to 1 year adjusted for baseline visual acuity was the primary outcome measure. The primary analysis consisted of 3 pairwise comparisons of the mean change in the sham ϩ prompt laser group compared with each of the other 3 groups.
Sample size was estimated to be 842 eyes (ϳ701 study participants assuming 20% of study participants would have 2 study eyes) on the basis of an expected population difference in the letter score of 6.0 and standard deviation of the visual acuity letter score of 18, a correlation between baseline and 1-year scores of 0.48, a type 1 error rate of 0.016 (adjusted for multiple comparisons and alpha spending for interim data reviews), and a power of approximately 90%.
The primary analysis included all randomized eyes and followed the intent-to-treat principle. Data were included in the 1-year analysis when an examination was performed between 308 and 420 days from randomization. When more than 1 visit occurred in this window, data from the visit closest to the 1-year target date were used. For eyes without 1-year data, the lastobservation-carried forward method was used to impute data for the primary analysis. Similar results (data not shown) were produced when analyses (1) used Rubin's method 14 to impute for missing data; (2) included only eyes with a completed 1-year 
examination and used the last visual acuity before additional treatment for those who received a treatment other than the randomly assigned treatment before the 1-year examination (perprotocol analysis); (3) included adjustment for the following potential confounders in addition to baseline visual acuity: age, gender, race/ethnicity, baseline hemoglobin A1c, baseline OCT central subfield thickness, and prior panretinal scatter photocoagulation and prior DME treatment at baseline; (4) were performed with outlying values truncated to 3 standard deviations from the mean; and (5) used van der Waerden's normal score transformation on the visual acuity scores. For analyses other than the primary analysis, only data from completed visits were used with no imputation for missing data. For some results, medians and interquartile ranges have been reported instead of, or in addition to, means and standard deviations to describe the distribution of the data. Analyses of the number of study treatments received before the 1-and 2-year visits included only the eyes of participants completing the 1-and 2-year visits.
Three pairwise comparisons were made for all analyses, except the ranibizumab groups were pooled for analysis of progression of diabetic retinopathy and all safety analyses. For all continuous outcomes, treatment group comparisons were made using analysis of covariance models with generalized estimating equations to account for correlated data from study participants with 2 study eyes. For binary outcomes, proportions similarly were compared between treatment groups using logistic regression models with generalized estimating equations. All analyses included adjustment for baseline visual acuity. In addition, models in which the central subfield thickness was the outcome included baseline central subfield thickness as a covariate, and models with retinal volume as the outcome included both baseline central subfield thickness and retinal volume as covariates. Similar analyses were performed on 2-year results. All P values are 2-sided. SAS version 9.1 (SAS Inc, Cary, NC) was used for all analyses.
Results
Between March of 2007 and December of 2008, 691 study participants (mean age 63Ϯ10 years; 44% women) were enrolled, 163 (24%) with 2 study eyes. The mean baseline visual acuity letter score in study eyes was 63Ϯ12 (ϳ20/63Ϯ2.4 lines), and the mean OCT central subfield retinal thickness was 405Ϯ134 m. The 854 study eyes were assigned to either sham ϩ prompt laser (nϭ293), ranibizumab ϩ prompt laser (nϭ187), ranibizumab ϩ deferred laser (nϭ188), or triamcinolone ϩ prompt laser (nϭ186). The baseline characteristics of the 4 groups were similar (Table 2 , available at http://aaojournal.org).
Follow-Up
The follow-up status for all study participants (eyes) is shown in Figure 1 (available at http://aaojournal.org). Thirteen study participants (2%) died before the 1-year primary outcome visit and 15 participants died subsequently of causes apparently unrelated to study treatment. For the remaining study participants, the 1-year primary outcome visit was completed for 94% to 96% of eyes in the 4 treatment groups. Those who completed the 1-year primary outcome visit completed 94% of the non-annual visits before 1 year. Baseline visual acuity was similar in the 55 study eyes of the 44 study participants who did not complete the 1-year primary outcome visit compared with the 799 eyes of the 647 study participants who completed the 1-year primary outcome visit (data not shown). The 2-year visit was completed for 484 eyes (57%), with 267 (31%) still pending, as of February 8, 2010 .
Treatments
Sham Injections and Intravitreal Study Drug Injections. For each study participant, there were 13 possible sham or study drug injections during the first year of follow-up. The median (25th, 75th percentile) number of sham injections before the 1-year primary outcome visit was 11 (8, 13) in the sham ϩ prompt laser group (of note, this excludes 56 eyes among 163 participants with 2 study eyes that were unmasked at baseline because the study participant's other eye was in the ranibizumab ϩ deferred laser group, precluding sham injections for the study eye assigned to sham ϩ prompt laser). The median number of study drug injections before the 1-year primary outcome visit was 8 (6, 10) ranibizumab injections (of 13 maximally possible injections) in the ranibizumab ϩ prompt laser group, 9 (6, 11) ranibizumab injections (of 13 maximally possible injections) in the ranibizumab ϩ deferred laser group, and 5 (3, 7) sham injections (of 9 maximally possible sham injections) and 3 (2, 4) triamcinolone injections (of 4 maximally possible triamcinolone injections) for a total of 13 maximally possible sham plus triamcinolone injections in the triamcinolone ϩ prompt laser group (Fig 2, available at http://aaojournal.org).
Retreatments Relative to 'Success' and 'Failure' Criteria. At the 16-week study visit, 47 (25%) of the 187 eyes in the ranibizumab ϩ prompt laser group and 41 (22%) of the 188 eyes in the ranibizumab ϩ deferred laser group met 'success' criteria (visual acuity letter score Ն84 [ϳՆ20/20] or OCT central subfield Ͻ250 m) and did not receive an injection. A total of 17 eyes (9%) in the ranibizumab ϩ prompt laser group and 15 eyes (8%) in the ranibizumab ϩ deferred laser group met 'success' criteria at 16 weeks and did not receive an additional injection before the 1-year primary outcome visit. At the 1-year primary outcome visit, 89 (32%) of the eyes in the sham ϩ prompt laser group, 109 (64%) of the eyes in the ranibizumab ϩ prompt laser group, 92 (52%) of the eyes in the ranibizumab ϩ deferred laser group, and 98 (56%) of the eyes in the triamcinolone ϩ prompt laser group met the 'success' criteria, including 23 (8%), 23 (13%), 23 (13%), and 19 (11%), respectively, with a visual acuity letter score Ն84 (ϳՆ20/ 20). 'Failure' criteria were met in 10 (4%), 3 (2%), 1 (1%), and 3 (2%) of the eyes in these 4 groups, respectively, during the first year of follow-up. Sham or study drug injections were not required for eyes meeting 'success' or 'failure' criteria.
Retreatments through Year 2. For the 218 study participants (58%) with 2 years of follow-up in the ranibizumab groups, there was a maximum of 25 possible ranibizumab injections. The median (25th, 75th percentile) number of ranibizumab injections between the 1-year visit, inclusive, and before the 2-year visit were 2 (0, 4) and 3 (1, 7) in the ranibizumab ϩ prompt laser group and the ranibizumab ϩ deferred laser group, respectively, for a total of 11 (7, 14) and 13 (8, 17) injections from baseline to the 2-year visit. Only 32% of participants in the ranibizumab ϩ prompt laser group and 21% of participants in the ranibizumab ϩ deferred laser group had no ranibizumab injections between the 1-and 2-year visits. The 103 study participants (55%) with 2 years of follow-up in the triamcinolone ϩ prompt laser group received 1 (0, 2) triamcinolone injection between the 1-year visit, inclusive, and before the 2-year visit for a total of 4 (3, 5) from baseline to the 2-year visit of a total of 8 maximum possible injections.
Focal/Grid Laser Treatments. The distribution of laser treatments before the 1-and 2-year visits are shown in Table 3 (available at http://aaojournal.org). The median (25th, 75th percentile) number of focal/grid photocoagulation treatments before the 1-year primary outcome visit was 3 (2, 3) in the sham ϩ prompt laser group, 2 (1, 3) in the ranibizumab ϩ prompt laser group, and 2 (1, 3) in the triamcinolone ϩ prompt laser group. In the ranibizumab ϩ prompt laser group, after baseline and before Ophthalmology Volume xx, Number x, Month 2010 4 
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the 1-year primary outcome visit, 53 (31%) study eyes received no additional focal/grid laser treatments, 54 (32%) received only 1 additional focal/grid laser treatment, 46 (27%) received only 2 additional focal/grid laser treatments, and 18 (11%) received 3 additional focal/ grid laser treatments. Focal/grid laser treatment was not permitted in the ranibizumab ϩ deferred laser group until the 24-week study visit; from the 24-week study visit and before the 1-year primary outcome visit, 128 (72%) of these study eyes received no focal/ grid laser treatment, 35 (20%) received only 1 focal/grid laser treatment, and 15 (8%) received 2 focal/grid laser treatments. Forty-seven percent of the sham ϩ prompt laser group, 57% of the ranibizumab ϩ prompt laser group, 72% of the ranibizumab ϩ deferred laser group, and 46% of the triamcinolone ϩ prompt laser group received no focal/grid laser treatments between the 1-and 2-year visits.
Alternative Treatments. Some eyes in the study were switched from the randomly assigned treatment to an alternative treatment during the first 2 years of follow-up because "failure" or "futility" criteria were met or the treating investigator determined deviating from the protocol would be in the best interest of the study participant as a patient. In the sham ϩ prompt laser group, this occurred in 14 eyes during the first year and in 29 eyes during the second year. Of these eyes, 5 and 20, respectively, met the "failure" or "futility" criteria before receiving alternative treatment. In the ranibizumab ϩ prompt laser group, 1 eye that met "failure" criteria received alternative treatment during the first year and 1 eye that met "failure" criteria received alternative treatment during the second year. There were no eyes in the ranibizumab ϩ deferred laser group that received alternative treatment during the first or second year of follow-up. In the triamcinolone ϩ prompt laser group, 1 and 3 eyes received alternative treatment during the first and second years, respectively. One of the 3 eyes in the second year of follow-up did not meet "failure" or "futility" criteria (Table  4 , available at http://aaojournal.org, lists the alternative treatments received).
Injection Treatment Compliance. Before the 1-year primary outcome visit, when a sham injection was required per protocol at each visit, the sham ϩ prompt laser group was given 96% (1288) of the required sham injections. Required study drug injection rates in the 3 active treatment groups were 95% (462 injections), 97% (525 injections), and 97% (673 injections) in the ranibizumab ϩ prompt laser group, ranibizumab ϩ deferred laser group, and triamcinolone ϩ prompt laser group, respectively. Success with Masking of Sham Injections. At the 1-year primary outcome visit, study participants were asked to guess their treatment group assignment. Among the 430 study participants with 1 study eye who completed the masking questionnaire and had received only the randomized treatment, the correct assignment was stated by 10% of the sham ϩ prompt laser group, 88% of the ranibizumab ϩ prompt laser group, 90% of the ranibizumab ϩ deferred laser group, and 44% of the triamcinolone ϩ prompt laser group. Among the 117 study participants with 2 study eyes who completed the unmasking questionnaire and had received only the randomized treatment, the correct assignment was stated for both eyes by 28% in ranibizumab ϩ prompt laser group, 23% of the ranibizumab ϩ deferred laser group, and 3% of the triamcinolone ϩ prompt laser group.
Effect of Treatment on Visual Acuity
As shown in Table 5 , for the 1-year primary outcome, the mean change Ϯ standard deviation in the visual acuity letter score from baseline was significantly greater in the ranibizumab ϩ prompt laser group (ϩ9Ϯ11, PϽ0.001) and ranibizumab ϩ deferred laser group (ϩ9Ϯ12, PϽ0.001) but not in the triamcinolone ϩ prompt laser group (ϩ4 Ϯ13, Pϭ0.31) compared with the sham ϩ prompt laser group (ϩ3Ϯ13). The results (Table 5 ) reflected both a greater proportion of eyes with a substantial improvement of Ն10 letters (50% and 47%) and Ն15 letters (30% and 28%) and a lower proportion of eyes with a substantial worsening of Ն10 letters (4% and 3%) and Ն15 letters (2% and 2%) in the 2 ranibizumab groups compared with the sham ϩ prompt laser group (28% and 15% for Ն10 and Ն15 letter gain, respectively, and 13% and 8% for Ն10 and Ն15 letter loss, respectively). Outcomes at 2 years (Table 6 , available at http://aaojournal.org) generally mirrored the 1-year primary outcome results. The distribution of the visual acuity letter score at the 1-and 2-year visits is shown in Table 7 (available at http://aaojournal.org).
Most of the overall improvement in mean visual acuity (Fig 3) and proportion with Ն10 letter improvement from baseline ( Fig  4A) within the ranibizumab-treated groups occurred by the 8-week study visit, with continued improvement through the 1-year primary outcome visit and stabilization thereafter. In contrast, the triamcinolone ϩ prompt laser group showed a more complex picture with improvement in the change in mean visual acuity through the 24-week visit, with decline thereafter (Fig 3) , whereas the proportion with Ն10 letter improvement gradually increased through 24 weeks, then decreased to 68 weeks and gradually increased again (Fig 4A) . The sham ϩ prompt laser group showed gradual improvement in these outcomes during the first year with stabilization thereafter. Few eyes deteriorated by Ն10 letters from baseline in the ranibizumab groups, whereas the proportion with this outcome in the triamcinolone ϩ prompt laser group and sham ϩ prompt laser group gradually increased throughout at least the first year (Fig 4B) .
By limiting the analysis to the 273 eyes that were pseudophakic at baseline, results appeared similar to the overall results for the sham ϩ prompt laser and the 2 ranibizumab groups at 1 and 2 years. However, for the 62 pseudophakic eyes at baseline in the triamcinolone ϩ prompt laser group, visual acuity results were substantially better than for phakic eyes such that the degree of improvement appeared comparable to that of the pseudophakic eyes in the ranibizumab groups and superior to that of the pseudophakic eyes in the sham ϩ prompt laser group at 1 year (Table  8) There was no obvious clinically important difference in results at the 1-year primary outcome visit for any other of the following subgroups: prior treatment for DME, baseline visual acuity, baseline OCT-measured central subfield thickening, baseline level of diabetic retinopathy determined by grading of fundus photographs, or description of edema by the treating ophthalmologist as predominantly focal or predominantly diffuse (Table 8) . One-year primary outcome results were similar to the overall results when limited to study participants with 2 study eyes ( Table 9 , available at http://aaojournal.org) and when excluding eyes from any clinical site with a baseline central subfield thickness Ͻ250 m (Table 10 , available at http://aaojournal.org).
Effect of Treatment on Retinal Thickening
At the 1-year primary outcome visit, OCT results (Table 11 ; Fig 6; Figs 7 and 8, available at http://aaojournal.org) in the sham ϩ prompt laser and the ranibizumab groups generally paralleled the overall visual acuity results, favoring the ranibizumab groups. In the triamcinolone ϩ prompt laser group the reduction in mean central subfield thickness was greater than in the sham ϩ prompt laser group and comparable with the ranibizumab groups. The pattern of OCT results were similar regardless of whether baseline central subfield thickness was Ͻ400 m or Ն400 m (Table 11) .
The change in OCT from the 1-to 2-year visit (Table 12, 
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acuity from the 1-to 2-year visit (Fig 3) differed among the treatments. For the ranibizumab groups, the OCT results remained relatively stable from the 1-to 2-year visit and paralleled the visual acuity results over this time. In the sham ϩ prompt laser group, the OCT results from the 1-to 2-year visit did not parallel the visual acuity results because the mean change in visual acuity from baseline did not continue to increase from the 1-to 2-year visit, even though the mean central subfield thickness continued to decrease during this time. Unlike the ranibizumab groups and sham ϩ prompt laser group, in the triamcinolone ϩ prompt laser group, the mean central subfield thickness increased from the 1-to 2-year visit and paralleled the slight decline in mean visual acuity from the 1-to 2-year visit. The OCT retinal volume measurements (Table 13 , available at http://aaojournal.org) at the 1-year primary outcome visit were similar to OCT central subfield thickness measurements (Table 11) . CI ϭ confidence interval; SD ϭ standard deviation. *Visits occurring between 308 and 420 days (between 44 and 60 wks) from randomization were included as 1-yr visits. When Ͼ 1 visit occurred in this window, data from the visit closest to the 1-yr target date were used. For other eyes without any 1-yr data (19 eyes in the sham ϩ prompt laser group, 16 eyes in the ranibizumab ϩ prompt laser group, 10 eyes in the ranibizumab ϩ deferred laser group, and 10 eyes in the triamcinolone ϩ prompt laser group), the last observation carried forward method was used to impute data for the primary analysis. † Analysis of covariance adjusted for baseline visual acuity and correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons. ‡ Adjusted for correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons. § Logistic regression adjusted for correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons.
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Effect of Treatment on Level of Diabetic Retinopathy
Eyes assigned to the ranibizumab-treated groups or the triamcinolone ϩ prompt laser group were less likely to show progression of diabetic retinopathy from baseline to the 1-year primary outcome visit as graded on fundus photographs compared with the sham ϩ prompt laser group ( Values that were Ϯ30 letters were assigned a value of 30. P values for difference in mean change in visual acuity from sham ϩ prompt laser at 52 weeks: ranibizumab ϩ prompt laser Ͻ0.001, ranibizumab ϩ deferred laser Ͻ0.001, and triamcinolone ϩ prompt laser groups ϭ 0.31. Each visit week includes visits that are Ϯ14 days, except the 52-week visit, which includes visits that occur between 308 and 420 days (between 44 and 60 weeks) from randomization, and the 104-week visit, which includes visits that occur between 616 and 840 days (between 88 and 120 weeks) from randomization. Figure 4 . A, Ten letter or greater improvement in visual acuity at follow-up visits. P values for difference in proportion of Ն10 letter improvement in visual acuity from sham ϩ prompt laser at the 52-week visit: ranibizumab ϩ prompt laser Ͻ0.001, ranibizumab ϩ deferred laser Ͻ0.001, and triamcinolone ϩ prompt laser ϭ 0.16. Each visit week includes visits that are Ϯ14 days, except the 52-week visit, which includes visits that occur between 308 and 420 days (between 44 and 60 weeks) from randomization, and the 104-week visit, which includes visits that occur between 616 and 840 days (between 88 and 120 weeks) from randomization. B, Ten letter or greater loss in visual acuity at follow-up visits. P values for difference in proportion of 10 letter loss in visual acuity from sham ϩ prompt laser at the 52-week visit: ranibizumab ϩ prompt laser Ͻ0.001, ranibizumab ϩ deferred laser Ͻ0.001, and triamcinolone ϩ prompt laser ϭ 0.75. Each visit week includes visits that are Ϯ14 days, except the 52-week visit, which includes visits that occur between 308 and 420 days (between 44 and 60 weeks) from randomization, and the 104-week visit, which includes visits that occur between 616 and 840 days (between 88 and 120 weeks) from randomization.
DRCR Network Writing Committee
cases of infectious endophthalmitis (1 after a study injection at baseline, 1 after an injection at 4 weeks, and 1 after an injection at 56 weeks) following the 3973 ranibizumab injections (0.08%; 95% confidence interval [CI] 0.02% to 0.22%) among 375 study participants (0.8%; 95% CI, 0.2% to 2%). In these 3 cases, the maximum visual acuity letter score after the infectious endophthalmitis was unknown in the first case because of lack of follow-up after the 1-week study visit, 73 (ϳ20/40) in the second case, and 58 (ϳ20/80) in the third case. In addition, there was 1 case of inflammatory pseudoendophthalmitis after the 685 triamcinolone injections among 186 study participants (0.5%; 95% CI, 0.01% to 3%). There was 1 case of progression of traction retinal detachment that occurred in the ranibizumab ϩ deferred laser group noted at an unscheduled visit 1 week before the 32-week study visit and after the eighth ranibizumab injection and 1 focal/ grid photocoagulation. This one case had extramacular traction retinal detachment and prior panretinal photocoagulation at baseline that were considered stable before randomization and was among the 111 eyes in the ranibizumab groups with prior panretinal photocoagulation, evidence of proliferative diabetic retinopathy, or both, at baseline. Vitrectomy was uncommon among all 4 treatment groups, and there were 5 retinal vein occlusions (1 in the sham ϩ prompt laser group, 1 in each of the ranibizumab groups, and 3 in the triamcinolone ϩ prompt laser group). The occurrence of IOP elevation Ͼ10 mmHg from baseline, IOP Ͼ30 mmHg, or initiation of IOP-lowering medications not in use at study entry at 1 or more visits during 2 years of follow-up was more frequent in eyes in the triamcinolone ϩ prompt laser group than in the ranibizumab groups or the sham ϩ prompt laser group (93 [50%] vs. 34 [9%] or 32 [11%], respectively; PϽ0.001 for both comparisons). Glaucoma surgery was performed in 4 eyes (1 eye in the sham ϩ prompt laser group, 1 eye in the ranibizumab ϩ prompt laser group, and 2 eyes in the triamcinolone ϩ prompt laser group). Among the subgroup of 62 pseudophakic eyes at baseline in the triamcinolone ϩ prompt laser group, 30 (48%) had Ն1 of the ocular hypertension events described above, compared with 10 (10%) and 15 (14%) among the 101 and 110 pseudophakic eyes at baseline in the sham ϩ prompt laser and ranibizumab groups, respectively. The cumulative percentage of eyes in the triamcinolone ϩ prompt laser group that underwent cataract surgery over the 2 years of follow-up was substantially greater compared with the sham ϩ prompt laser group or the ranibizumab groups (59% vs. 14% and 14%, respectively; PϽ0.001 for both comparisons) (Fig 9) .
Systemic Adverse Events. There were no systemic adverse events with a difference in frequency among the 4 groups that could not be attributed to chance. In particular, there was no indication of an increase in the rate of cardiovascular or cerebrovascular events in the ranibizumab groups compared with the other groups (Table 17 ). The mean number of systemic adverse events reported per participant through 2 years with 1 study eye was 3Ϯ3 in the sham group, 3Ϯ3 in the 2 ranibizumab groups combined, and 3Ϯ4 in the triamcinolone group. All systemic adverse events and study eye ocular adverse events reported by the site are shown in Tables 18 and 19 (available at http://aaojournal.org).
Discussion
In this randomized clinical trial, intravitreal ranibizumab, either with prompt or deferred (Ն24 weeks) focal/grid laser, resulted in superior visual acuity and OCT outcomes compared with focal/grid laser treatment without ranibizumab at 
both 1 and 2 years of follow-up. Approximately half of the eyes treated with ranibizumab had substantial visual acuity improvement (Ն10 letter gain from baseline), whereas approximately 30% gained Ն15 letters, equivalent to 3 lines on the eye chart, a reduction of the visual angle by half; substantial loss (Ն10 letter loss from baseline) was uncommon. Among eyes treated with intravitreal ranibizumab, results were similar whether focal/grid laser was given starting with the first ranibizumab injection or it was deferred for at least 6 months. Overall, intravitreal triamcinolone combined with focal/grid laser did not result in superior visual acuity outcomes compared with laser without triamcinolone, although it did result in a greater reduction in retinal thickening at 1 year but not 2 years compared with laser alone. However, in an analysis limited to pseudophakic eyes, the triamcinolone ϩ prompt laser group's outcome for visual acuity was of similar magnitude to that of the 2 ranibizumab groups, suggesting that cataract formation, cataract surgery, or both, may have affected visual acuity outcomes adversely among phakic eyes in the triamcinolone ϩ prompt laser group. If ranibizumab is to be given as it was applied in this study, the 1-and 2-year data indicate a need to follow eyes continuously undergoing this treatment because the results indicate that additional ranibizumab or focal/grid laser, or both, are needed in most eyes through at least 2 years, even if 'success' criteria are met early in the course of treatment. According to the DRCR.net retreatment algorithm used in this study, eyes assigned to ranibizumab that met 'success' criteria at the 16-week study visit were not required to have continued injections unless visual acuity worsened or macular edema returned. Approximately two thirds of these early successes received additional ranibizumab at Ն1 visit after the 16-week visit. Furthermore, not all eyes avoided the need for focal/grid laser when following the protocol assigned to the ranibizumab ϩ deferred laser group. Specifically, for eyes assigned to ranibizumab ϩ deferred laser, approximately one third required focal/grid laser at least once between the 24-week and the 1-year study visits when the retreatment algorithm was followed.
These results are based on rigorous adherence to a detailed retreatment protocol facilitated by a web-based, realtime data-entry system that provided feedback to the treating physician regarding the treatment (intravitreal/sham injection or focal/grid photocoagulation) and subsequent follow-up interval to be prescribed at each follow-up visit. The retreatment algorithm followed in the study may appear detailed, but the underlying rationale is to continue anti-VEGF and focal/grid laser treatment, as needed, until stabilization or lack of further improvement is noted.
The details of the retreatment algorithm represent an attempt to have a rigorous protocol within a clinical trial that can address the many possible courses of the disease (variable improvements and deteriorations in visual acuity and retinal thickness). In addition, the retreatment algorithm attempts to minimize situations when retreatment might be recommended by the algorithm and yet not judged to be desired by the investigator, as might occur if monthly retreatments for 1 or 2 DRCR Network Writing Committee ⅐ Laser-Ranibizumab-Triamcinolone RCT for DME
years were required. Once retreatment is withheld at a particular visit in lieu of monthly treatments for 1 or 2 years, the algorithm is designed to try to identify when the investigator might believe there is a need to reinitiate intravitreal anti-VEGF treatment, focal/grid laser treatment, or both, thereby avoiding substantial vision loss and a regimen that requires monthly treatments regardless of the clinical course. The relatively stable visual acuity outcomes between the 1-and 2-year visits in the ranibizumab groups suggest that this detailed retreatment algorithm accomplished these goals, although it is unknown whether treatment given every 4 weeks would have led to better outcomes. The impact of different retreatment approaches or use of other anti-VEGF drugs (e.g., bevacizumab) in clinical practice compared with this DRCR.netspecific protocol on visual acuity outcomes cannot be determined from this study. We found no evidence that ranibizumab or triamcinolone is associated with an increased risk of systemic side effects CI ϭ confidence interval; logOCT ϭ logarithmic transformation of optical coherence tomography; OCT ϭ optical coherence tomography; SD ϭ standard deviation. *Visits occurring between 308 and 420 days (between 44 and 60 wks) from randomization were included as 1-yr visits. When Ͼ 1 visit occurred in this window, data from the visit closest to the 1-yr target date were used. † Missing (or ungradeable) data as follows for the sham ϩ prompt laser, ranibizumab ϩ prompt laser, ranibizumab ϩ deferred laser, and triamcinolone ϩ prompt laser groups, respectively: 22, 16, 13, 13. ‡ Analysis of covariance adjusted for baseline OCT retinal thickness and visual acuity and correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons. § Logistic regression adjusted for baseline OCT retinal thickness and visual acuity and correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons. 
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or overall mortality, including cerebrovascular accidents and cardiovascular events. However, in view of the low number of observed events, a small increased risk cannot be ruled out. With respect to ocular adverse events, there was 1 case of progressive traction retinal detachment among the 375 eyes (0.3%) assigned to ranibizumab; this case had extramacular traction detachment before randomization, did not develop until 3 weeks after the 8 monthly consecutive intravitreal ranibizumab injections (when the concentration of the antibody in the vitreous should be low), and was among the 111 ranibizumab-treated eyes with prior panretinal photocoagulation, evidence of proliferative diabetic retinopathy, or both, at baseline. This complication has been suggested to be associated with intravitreal anti-VEGF injections in case series, 15, 16 although if ranibizumab truly is causative, the event seems to be uncommon, and the only case identified in this study did not have progressive detachment with vision loss until 8 monthly ranibizumab injections had been given. In fact, eyes in the ranibizumab groups were less likely to show progression of diabetic retinopathy, development of vitreous hemorrhage, or need for panretinal photocoagulation. More information regarding the possibility of this cause-and-effect relationship may be forthcoming in another DRCR.net protocol evaluating ranibizumab in the setting of proliferative diabetic retinopathy with DME.
17
There were 3 cases of injection-related endophthalmitis, including 1 in which no antiseptic was applied to the injection site, which represented 1 of only 8 injections in which povidone iodine was not applied to the injection site. Fluorescein angiograms were not required in this study, so this study cannot determine whether there were cases of development or progression of macular capillary nonperfusion with anti-VEGF injections, as has been suggested in a case series.
18 However, there were few eyes assigned to ranibizumab with a loss of Ն10 letters, suggesting that if this complication does occur in this setting, it is relatively uncommon and does not outweigh the benefits of treatment. As has been reported in prior studies, 19 -21 intravitreal triamcinolone was associated in this study with an increased risk of elevated IOP and cataract.
Subgroup analysis among pseudophakic eyes at baseline suggested that DRCR.net treatment using intravitreal triamcinolone combined with prompt focal/grid laser results in superior visual acuity outcomes compared with laser alone, although, as noted above, there is an elevated risk of increased IOP. These results are in contrast with a similar group of eyes treated with the same intravitreal triamcinolone formulation but without prompt focal/grid laser, 5 in which outcomes for pseudophakic eyes at baseline were not superior using intravitreal triamcinolone compared with focal/grid laser. Although these differences in outcome could be due to differences in the characteristics of eyes between these 2 studies, it is logical to assume that the combination of 2 monotherapies (focal/grid laser and intravitreal triamcinolone) for DME in pseudophakic eyes, each of which seems to be superior to no treatment, 5 is superior to focal/ grid laser alone for pseudophakic eyes.
Some of the strengths of this study include its size, which provided relatively narrow CIs in the results presented, and good adherence to a strict protocol across multiple communityand institutional-based clinical sites throughout the United States. In addition, the data suggest that most study participants assigned to sham injection were successfully masked, because most believed they received actual injections. The data among study participants with 2 study eyes were similar to the overall Figure 6 . Optical coherence tomography central subfield thickness Ͻ250 m with at least a 25 m decrease in thickness from baseline at follow-up visits. P values for difference in proportion in OCT central subfield thickness Ͻ250 m with at least a 25 m decrease in thickness from sham ϩ prompt laser at the 52-week visit: ranibizumab ϩ prompt laser Ͻ0.001, ranibizumab ϩ deferred laser ϭ 0.001, and triamcinolone ϩ prompt laser Ͻ0.001. Each visit week includes visits that are Ϯ14 days, except the 52-week visit, which includes visits that occur between 308 and 420 days (between 44 and 60 weeks) from randomization, and the 104-week visit, which includes visits that occur between 616 and 840 days (between 88 and 120 weeks) from randomization. OCT ϭ optical coherence tomography.
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results, suggesting there was little or no contralateral effect of ranibizumab on the fellow eye assigned to laser and no intravitreal injection, and providing a cohort in which all genetic, systemic, and environmental effects on DME should be well controlled. Although the 2-year data support the findings at 1 year, the 3-year data should help determine whether improvements noted to date are sustained and how often intravitreal ranibizumab or focal/grid laser is needed over time, whether starting with ranibizumab with prompt laser or ranibizumab with deferred laser. Some weaknesses of the study include the apparent complexity of the retreatment algorithm. Study participants assigned to the ranibizumab ϩ deferred laser group or with 2 study eyes could not be masked if 1 eye was assigned to the ranibizumab ϩ deferred laser group because prompt laser was not performed in that eye, thus unmasking the ranibizumab ϩ deferred laser group to the treatment assignment. It also should be noted that neither intravitreal triamcinolone nor ranibizumab is currently approved for DME by the Food and Drug Administration; use of intravitreal ranibizumab or intravitreal triamcinolone for DME would be an off-label indication at this time.
The observed benefits of intravitreal anti-VEGF treatment for DME in this study are consistent with shorter-term improvements in visual acuity outcomes and resolution of DME on OCT noted with bevacizumab 22 and ranibizumab. 9 How- Figure 9 . Cumulative probability of cataract surgery through 2 years of follow-up for all eyes phakic at baseline. Eyes pending a 2-year visit or that were lost to follow-up were censored at their last visit. N is the number of eyes phakic at baseline. *Number of eyes at the start of the interval without previous cataract surgery. **Number of eyes with cataract surgery during the subsequent 4-month period. IOP ϭ intraocular pressure *One case unrelated to study drug injection (after cataract extraction) in the sham ϩ prompt laser group; 2 cases related to study drug injection in the ranibizumab groups (0.06% of ranibizumab injections given). One case occurred at baseline and 1 at the 4-wk visit. Endophthalmitis was defined as any patient having an intravitreal or anterior chamber tap for presumed endophthalmitits or treated for infectious endophthalmitis regardless of whether a tap was performed or whether a culture is positive. † One case was unrelated to the study drug injection (vitreous opacity with hypopyon), and 1 case was related to study drug injection in the triamcinolone group. Pseudoendophthalmitis was defined on the basis of investigator diagnosis and patient not tapped or treated for infectious endophthalmitis. ‡ Includes 2 central retinal vein occlusions and 2 branch retinal vein occlusions. § Includes 1 progressive traction retinal detachment with proliferative diabetic retinopathy and prior panretinal photocoagulation at baseline. Visual acuity remained stable, within 5 letters of the baseline visual acuity letter score of 66 (20/50), while ranibizumab was given every 4 wks through the 24-wk visit when focal/grid laser also was applied. Ranibizumab was given again at the 28-wk visit and 5 wks later, sudden vision loss was reported, and a table-top detachment involving the central macula was noted at an unscheduled visit with a visual acuity letter score of 48 (20/125). Vitrectomy surgery was delayed for several weeks because of other medical problems; after surgery, the visual acuity letter score remained 0 (Ͻ20/800). ʈ Excludes eyes with IOP-lowering medications at baseline.
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ever, to our knowledge, no previous publications evaluating anti-VEGF drugs for DME have compared this treatment with concurrent controls receiving focal/grid laser with follow-up through at least 1 year. Other studies are under way that are comparing intravitreal ranibizumab alone, or in combination with laser, with laser alone over 1 year 23 and comparing intravitreal ranibizumab alone with sham. 24, 25 Results from these and other studies should complement knowledge regarding the safety and efficacy of ranibizumab and other anti-VEGF drugs, alone, or in combination with laser, for the treatment of DME. The aggregate information from these studies also would be necessary to assess cost-effectiveness.
In conclusion, focal/grid laser has been the mainstay of treatment for DME during the past 25 years. On the basis of the data from this DRCR.net protocol, intravitreal ranibizumab with deferred (Ն24 weeks) or prompt focal/grid laser is superior to focal/grid laser alone for the treatment of DME involving the center of the macula through at least 1 year of follow-up, with significantly more eyes gaining substantial vision and significantly fewer eyes losing substantial vision. Intravitreal ranibizumab as applied in this study, although uncommonly associated with endophthalmitis and theoretically associated with an increased risk of traction retinal detachments in eyes with proliferative diabetic retinopathy, should be considered for patients with DME and characteristics similar to those of the cohort in this clinical trial. In pseudophakic eyes, intravitreal triamcinolone with prompt focal/grid laser may be equally effective as ranibizumab at improving visual acuity and reducing retinal thickening but is associated with an increased risk of elevated IOP. Further follow-up is needed to determine even longer-term safety and efficacy of ranibizumab in the treatment of DME. DRCR Network Writing Committee ⅐ Laser-Ranibizumab-Triamcinolone RCT for DME This article contains online-only material. The following should appear online-only: Tables 1, 2 , 3, 4, 6, 7, 9, 10, 12, 13, 14, 16, 18, and 19; Figures 1, 2, 5, 7, and 8 The funding organization (National Institutes of Health) participated in oversight of the conduct of the study and review of the manuscript but not directly in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation of the manuscript. Genentech provided the ranibizumab for the study, and Allergan, Inc., provided the triamcinolone for the study. In addition, Genentech and Allergan, Inc., provided funds to the DRCR.net to defray the study's clinical site costs. As described in the DRCR.net Industry Collaboration Guidelines (available at www.drcr.net), the DRCR.net had complete control over the design of the protocol, the ownership of the data, and all editorial content of presentations and publications related to the protocol. A complete list of all DRCR.net investigator financial disclosures can be found at www.drcr.net 
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Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema 000
The Diabetic Retinopathy Clinical Research Network
Intravitreal ranibizumab therapy with prompt or delayed (Ն24 weeks) focal/grid laser is more effective than laser alone in the treatment of diabetic macular edema, although intravitreal injections are uncommonly associated with endophthalmitis.
U N C O R R E C T E D P R O O F Appendix 1. Diabetic Retinopathy Clinical Research Network Laser-RanibizumabTriamcinlone Study Treatment
Baseline treatment. Injections of 0.5-mg ranibizumab and 4-mg preservative free triamcinolone (Trivaris, Allergan, Inc., Irvine, CA) were administrated with a standardized intravitreal injection technique which included a povidone iodine prep of the conjunctiva. Antibiotics in the pre-, peri-, and post-injection period were optional. The sham injection procedure consisted of placing the hub of a syringe against the conjunctival surface following the povidone-iodine prep. Focal/grid photocoagulation was administered using a technique modified from the original Early Treatment Diabetic Retinopathy Study (ETDRS) protocol as described previously and used in prior Diabetic Retinopathy Clinical Research Network (DRCR.net) protocols. 26 The initial intravitreal (or sham) injection was given on the day of randomization. The 3 groups assigned to prompt laser received focal/grid photocoagulation 1 week (with a treatment window of 3 to 10 days) after the baseline intravitreal (or sham) injection.
Follow-up intravitreal study drug or sham retreatments through the 48-week study visit. The protocol required retreatment with intravitreal or sham injections (depending upon the randomized assignment at baseline) and focal/grid laser following guidelines outlined below, unless precluded by adverse events. The guidelines used to make retreatment decisions had different parameters for intravitreal or sham injections depending on which study visit was occurring. Prior to the 16-week study visit, treatment with sham or study drug was given every 4 weeks regardless of the visual acuity or optical coherence tomography (OCT) central subfield thickness. At the 16 and 20 week study visits, sham or study drug was required monthly unless 'success' criteria (defined as visual acuity letter score Ն84 (20/20) or OCT central subfield thickness Ͻ250; Table 1 , available at http:// aaojournal.org) was met, in which case sham or study drug injection was at investigator discretion. At each visit from 24 to 48 weeks, eyes were categorized as meeting either 'success' as defined above, 'improvement', 'no improvement', or 'failure' (defined below and Table 1 , available at http://aaojournal.org). 'Improvement' required a sham or study drug injection and was defined as an eye that did not meet criteria for success but in which either visual acuity had improved by Ն5 letters or OCT central subfield thickness had improved by Ն10% since the last non-sham injection or since baseline for the shamϩprompt laser group. If an eye was categorized as 'no improvement' because it met neither the criteria for 'success' or 'improvement', but had not yet met the criteria for 'failure' a sham or study drug injection could be given at investigator discretion. 'Failure' was defined as a visual acuity letter score 10 or more letters worse than the baseline score, OCT central subfield thickness Ն250 um, diabetic macular edema (DME) judged to be the cause of visual acuity loss and duration of at least 13 weeks since 'complete laser' (defined in Table 1 , available at http://aaojournal.org) had been given with no improvement since the last laser treatment. Eyes that met 'failure' criteria could be treated at investigator discretion with a sham or randomized study drug injection or with an 'alternative' treatment regimen (defined in Table 1 , available at http://aaojournal.org) other than that assigned at baseline, such as intravitreal bevacizumab or triamcinolone. Appendix 2 (available at http://aaojournal.org) provides a detailed flow chart of study drug or sham retreatments through the 48-week study visit.
Intravitreal study drug retreatments after the 48-week study visit. At and after the 1 year study visit (Appendix 3, available at http://aaojournal.org), sham injections were discontinued and follow-up study visits occurred at every 4 months instead of monthly for eyes in the shamϩprompt laser group and the triamcinoloneϩprompt laser group. Eyes in the two ranibizumab groups that met failure criteria also had study visits every 4 months. For eyes assigned to receive injections, the same retreatment criteria were followed as at the 24 to 48 week visit with two additional considerations. First, the treatment regimen could be at investigator discretion, including treatments other than the randomly assigned treatment, not only for eyes that met 'failure' criteria but also for eyes that met 'futility' criteria (defined below and Table 1 , available at http://aaojournal.org). 'Futility' criteria were defined similarly to failure criteria except that visual acuity was not required to be worse than baseline if it had been at least 29 weeks since 'complete laser' and all other criteria for 'failure' were met. Second, for eyes assigned to ranibizumab in which the injection was deferred at the current and previous two visits either due to 'success' or 'no improvement', as defined above, then the follow-up could be extended. 'Extended follow-up' (defined in Table 1 , available at http://aaojournal. org) visits occurred at intervals that were twice the time since the previous visit, up to a maximum of 16 weeks between study visits.
Follow-up focal/grid laser treatment. Application of focal/grid laser treatment at and after the 16-week study visit (Appendix 4, available at http://aaojournal.org) for each group except the ranibizumabϩdeferred laser group occurred 3 to 10 days following each intravitreal (or sham) injection unless one of the following was present at the time of the injection: (1) laser was given in the previous 13 weeks; (2) the investigator considered that 'complete laser' (direct treatment to all microaneurysms within areas of edema and grid treatment to all other areas of macular edema) had already been applied; or (3) OCT central subfield thickness was Ͻ250 microns and there was 'no edema threatening the center of the macula', defined as no edema within 500 microns of the center of the macula, no edema associated with lipid within 500 microns of the center of the macula, and no edema Ն 1 disc area within 1 disc area of the center of the macula (defined in Table 1 , available at http://aaojournal.org). For the ranibizumabϩdeferred laser group, at the 24-week and any later visit, if there was 'no improvement' as defined above from the last two study injections and the investigator believed that macular edema was present for which focal/grid laser was indicated, the eye was to receive focal/grid laser until the edema resolved or 'complete laser' was given using the same criteria defined for eyes assigned to 'prompt' focal-grid photocoagulation.
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Term Definition
ShamϩPrompt Laser group Eyes assigned to receive sham injection plus prompt (within one week) focal/grid photocoagulation RanibizumabϩPrompt Laser group Eyes assigned to receive 0.5 mg intravitreal ranibizumab plus prompt (within one week) focal/grid photocoagulation RanibizumabϩDeferred Laser group Eyes assigned to receive 0.5 mg intravitreal ranibizumab with deferred (Ն24 weeks) focal/grid photocoagulation TriamcinoloneϩPrompt Laser group Eyes assigned to receive 4 mg intravitreal triamcinolone plus prompt (within one week) focal/grid photocoagulation Focal/grid laser Focal/grid photocoagulation administered using modified ETDRS protocol 'Complete laser' Direct treatment to all microaneurysms within areas of macular edema and grid treatment to all other areas of macular edema 'Success' criteria relative to retreatment decisions Either visual acuity letter score Ն84 (20/20) or OCT central subfield thickness Ͻ250 microns since the last non-sham injection or since baseline for the shamϩprompt laser group 'Improvement' criteria relative to retreatment decisions Either visual acuity improved by Ն5 letters or OCT central subfield thickness improved by Ն10% since the last non-sham injection or since baseline for the shamϩprompt laser group 'No improvement' criteria relative to retreatment decisions Success and failure/futility criteria not met and visual acuity letter score improved by Ͻ5 letters (or worsened) and OCT central subfield thickness decreased by Ͻ10% (or increased) since the last non-sham injection or since baseline for the shamϩprompt laser group 'Failure' criteria relative to retreatment decisions Visual acuity 10 or more letters worse than baseline, OCT central subfield thickness Ն250 um, DME judged to be the cause of visual acuity loss, and at least 13 weeks since 'complete laser' had been given with 'no improvement' since the last laser treatment 'Futility' criteria relative to retreatment decisions After 52 week visit: OCT central subfield Ն250 um, DME judged to be the cause of visual acuity loss, and at least 29 weeks since 'complete laser' had been given with 'no improvement' since the last laser treatment 'Extended follow-up' After 52 week visit: Follow-up visit in twice the time interval since the last visit, up to a maximum of 16 weeks between study visits (applies to eyes assigned to ranibizumab in which the injection was repeatedly deferred either due to 'success' or 'no improvement') 'Alternative treatment' Treatment for DME other than the randomization-assigned regimen 'Edema involving the center of the macula'
OCT central subfield thickness Ն250 um 'Edema threatening the center of the macula' Edema on clinical exam within 500 microns of the foveal center or edema associated with lipid within 500 microns of the foveal center or 1 disc area of edema within 1 disc area of the foveal center DME ϭ diabetic macular edema; ETDRS ϭ Early Treatment Diabetic Retinopathy Study; OCT ϭ optical coherence tomography.
Ophthalmology Volume xx, Number x, Month 2010 15.e11 ) on OCT § Median (25th,75th percentile) 8.7 (7.8, 10.0) 8.4 (7.5, 9.6) 8.4 (7.4, 9.8) 8.5 (7.8, 9. DME ϭ diabetic macular edema; E-ETDRS © ϭ electronic Early Treatment Diabetic Retinopathy Study; ETDRS ϭ Early Treatment Diabetic Retinopathy Study; HbA1c ϭ hemoglobin A1c; IOP ϭ intraocular pressure; IVT ϭ intravitreal triamcinolone; NPDR ϭ non-proliferative diabetic retinopathy; OCT ϭ optical coherence tomography; PDR ϭ proliferative diabetic retinopathy; PRP ϭ panretinal photocoagulation; VEGF ϭ vascular endothelial growth factor. *Missing HbA1c data for 17, 3,7 and 8 study participants in the shamϩprompt laser, ranibizumab ϩ prompt laser, ranibizumabϩdeferred laser, and triamcinolone ϩ prompt laser groups, respectively. † Medical history of condition. ‡ One OCT central subfield thickness (CST) had an ineligible site OCT value (Ͻ250) and 60 had an ineligible OCT CST from reading center grading. All are included in this table. § Missing (or ungradeable) OCT and fundus photograph data as follows for the shamϩprompt laser, ranibizumab ϩ prompt laser, ranibizumabϩdeferred laser, and triamcinoloneϩprompt laser groups, respectively: central subfield (1 in the ranibizumabϩdeferred laser), retinal volume (73, 49, 42, 48) , and retinopathy severity (5, 3, 9, 2) . DRCR Network Writing Committee ⅐ Laser-Ranibizumab-Triamcinolone RCT for DME Ophthalmology Volume xx, Number x, Month 2010 15.e15 14 (25) 1 ( DRCR Network Writing Committee ⅐ Laser-Ranibizumab-Triamcinolone RCT for DME Ophthalmology Volume xx, Number x, Month 2010 15.e17 LOCF ϭ last observation carried forward. *Visits occurring between 308 and 420 days (between 44 and 60 weeks) from randomization were included as 1-year visits. When more than 1 visit occurred in this window, data from the visit closest to the 1-year target date were used. For other eyes without any 1-year data (19 eyes in the shamϩprompt laser group, 16 eyes in the ranibizumabϩprompt laser group, 10 eyes in the ranibizumabϩdeferred laser group, and 10 eyes in the triamcinoloneϩprompt laser group) the last observation carried forward method was used to impute data for the primary analysis. † Visits occurring between 616 and 840 days (between 88 and 120 weeks) from randomization were included as 2-year visits. When more than 1 visit occurred in this window, data from the visit closest to the 2-year target date were used. Figure 5 . Mean change in visual acuity at follow-up visits among eyes that were pseudophakic at baseline. Values of Ϯ30 or more letters were assigned a value of 30. Each visit week includes visits that are Ϯ14 days, except the 52-week visit, which includes visits that occur between 308 and 420 days (between 44 and 60 weeks) from randomization, and the 104-week visit, which includes visits that occur between 616 and 840 days (between 88 and 120 weeks) from randomization.
15.e14
ARTICLE IN PRESS U N C O R R E C T E D P R O O FARTICLE IN PRESS U N C O R R E C T E D P R O O F
15.e16
DRCR Network Writing Committee ⅐ Laser-Ranibizumab-Triamcinolone RCT for DME SD ϭ standard deviation; CI ϭ confidence interval *Visits occurring between 308 and 420 days (between 44 and 60 weeks) from randomization were included as 1-year visits. When more than 1 visit occurred in this window, data from the visit closest to the 1-year target date were used. For other eyes without any 1-year data (11 eyes in the shamϩprompt laser group, 4 eyes in the ranibizumabϩprompt laser group, 2 eyes in the ranibizumabϩdeferred laser group, and 5 eyes in the triamcinolneϩprompt laser group) the last observation carried forward method was used to impute data for the primary analysis. † Analysis of covariance adjusted for baseline visual acuity and correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons.
15.e18
Ophthalmology Volume xx, Number x, Month 2010 15.e19 CI ϭ confidence interval; SD ϭ standard deviation. ‡ Adjusted for correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons. *Visits occurring between 308 and 420 days (between 44 and 60 weeks) from randomization were included as 1-year visits. When more than 1 visit occurred in this window, data from the visit closest to the 1-year target date were used. For other eyes without any 1-year data (15 eyes in the shamϩprompt laser group, 14 eyes in the ranibizumabϩprompt laser group, 8 eyes in the ranibizumabϩdeferred laser group, and 8 eyes in the triamcinoloneϩprompt laser group) the last observation carried forward method was used to impute data for the primary analysis. † Analysis of covariance adjusted for baseline visual acuity and correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons. § Logistic regression adjusted for correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons.
DRCR Network Writing Committee ⅐ Laser-Ranibizumab-Triamcinolone RCT for DME 15.e20 Figure 7 . Two or more step improvement in the logarithmic transformation of OCT central subfield thickness from baseline. Each visit week includes visits that are Ϯ14 days, except the 52-week visit, which includes visits that occur between 308 and 420 days (between 88 and 120 weeks) from randomization, and the 104-week visit, which includes visits that occur between 616 and 840 days (between 88 and 120 weeks) from randomization. logOCT ϭ logarithmic transformation of optical coherence tomography calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounded to the nearest hundredth. (Ferris FL III, Miller KM, Glassman AR, Beck RW. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology. In Press.) Figure 8 . Mean change in OCT central subfield retinal thickening at follow-up visits. P values for difference in mean change in OCT central subfield retinal thickness from sham ϩ prompt laser at the 52-week visit: ranibizumab ϩ prompt laser Ͻ0.001, ranibizumab ϩ deferred laser Ͻ0.001, and triamcinolone ϩ prompt laser Ͻ0.001. Each visit week includes visits that are Ϯ14 days, except the 52-week visit, which includes visits that occur between 308 and 420 days (between 44 and 60 weeks) from randomization, and the 104-week visit, which includes visits that occur between 616 and 840 days (between 88 and 120 weeks) from randomization. OCT ϭ optical coherence tomography.
Ophthalmology Volume xx, Number x, Month 2010 15.e21 CI ϭ confidence interval; OCT ϭ optical coherence tomography; SD ϭ standard deviation. *Visits occurring between 616 and 840 days (between 88 and 120 weeks) from randomization were included as 2-year visits. When more than 1 visit occurred in this window, data from the visit closest to the 2-year target date were used. † Missing (or ungradeable) data as follows for the shamϩprompt laser, ranibizumabϩprompt laser, ranibizumabϩdeferred laser, and triamcinoloneϩprompt laser groups, respectively: 11, 7, 12, 10. ‡ Analysis of covariance adjusted for baseline OCT retinal thickness and visual acuity and correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons. § Logistic regression adjusted for baseline OCT retinal thickness and visual acuity and correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons. OCT ϭ optical coherence tomography; SD ϭ standard deviation; CI ϭ confidence interval. *Visits occurring between 308 and 420 days (between 44 and 60 weeks) from randomization were included as 1 year visits. When more than 1 visit occurred in this window, data from the visit closest to the 1-year target date were used. † Missing (or ungradeable) data as follows for the shamϩprompt laser, ranibizumabϩprompt laser, ranibizumabϩdeferred laser, and triamcinoloneϩprompt laser groups, respectively: 85, 54, 46, 55. ‡ Analysis of covariance adjusted for baseline OCT retinal volume, OCT retinal thickness and visual acuity and correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons.
DRCR Network Writing Committee ⅐ Laser-Ranibizumab-Triamcinolone RCT for DME IOP ϭ intraocular pressure *One case unrelated to study drug injection (following cataract extraction) in the shamϩprompt laser group; 1 case related to study drug injection and 1 case unrelated to injection (following cataract surgery) in the ranibizumabϩprompt laser group; 2 cases related to study drug injection in the ranibizumabϩdeferred laser group. The 3 cases related to study drug injection in the ranibizumab groups are 0.08% of ranibizumab study drug injections given. Endophthalmitis was defined as any patient having an intravitreal or anterior chamber tap for presumed endophthalmitis or treated for infectious endophthalmitis regardless of whether a tap was performed or whether a culture is positive. † One case unrelated to the study drug injection (vitreous opacity with hypopyon) and one case related to study drug injection in the triamcinolone group. Pseudoendophthalmitis was defined based on investigator diagnosis and patient not tapped or treated for infectious endophthalmitis. ‡ Includes 2 central retinal vein occlusions and 4 branch retinal vein occlusions. § Includes 1 traction retinal detachment with proliferative diabetic retinopathy and prior panretinal photocoagulation at baseline. Visual acuity had remained stable (within 5 letters) of the baseline visual acuity letter score of 66 (20/50) while ranibizumab was given every 4 weeks through the 24-week visit when focal/grid laser also was applied. Ranibizumab again was given at the 28-week visit and five weeks later, sudden vision loss was reported and a table top detachment involving the central macula was noted at an unscheduled visit with a visual acuity letter score of 48 (20/125). Vitrectomy surgery was delayed for several weeks because of other medical problems; following surgery, the visual acuity letter score remained 0 (Ͻ20/800). ʈ Excludes eyes with IOP lowering medications at baseline. Ophthalmology Volume xx, Number x, Month 2010 15.e31
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